title: Inhibitory effects of CIDR-based ovulation-synchronization protocols on uterine PGF2alpha secretion at the following luteal phase in early postpartum non-cycling beef cows.
abstract: We investigated whether CIDR-based ovulation-synchronization protocols inhibit secretion of prostaglandin (PG) F2alpha from the uterus in the following luteal phase in non-cycling beef cows. Ten early (a month) postpartum non-cycling Japanese Black beef cows were treated with (1) Ovsynch (GnRH analogue on Day 0, PGF2alpha analogue on Day 7, and GnRH analogue on Day 9; n=3), (2) Ovsynch+CIDR (Ovsynch protocol plus a CIDR for 7 days from Day 0; n=4), or (3) estradiol benzoate (EB) Ovsynch+CIDR (EB on Day 0 in lieu of the first GnRH treatment followed by the Ovsynch+CIDR protocol; n=3). An oxytocin challenge was administered on Day 24 to examine uterine PGF2alpha secretion. Plasma concentrations of 13,14-dihydro-15-keto- PGF2alpha were lower at 30-120 min after oxytocin administration in the Ovsynch+CIDR group and 75 min after administration in the EB Ovsynch+CIDR group than in the Ovsynch group (P<0.05). Plasma progesterone concentrations were higher from Days 1 to 7 in the Ovsynch+CIDR group and from Days 1 to 5 in the EB Ovsynch+CIDR group than in the Ovsynch group (P<0.05). The progesterone concentrations were higher on Days 27 and 29 in both CIDR-treated groups than in the Ovsynch group (P<0.05). In conclusion, in non-cycling beef cows, CIDR-based ovulation-synchronization protocols inhibit uterine PGF2alpha secretion in the following luteal phase and prevent premature luteolysis as is seen with the Ovsynch protocol.
authors.affiliation: Department of Advanced Pathobiology, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Japan.
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Sakase
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Kawate
authors.forename: Chikara
authors.initials: C
authors.lastname: Nakagawa
authors.forename: Moriyuki
authors.initials: M
authors.lastname: Fukushima
authors.forename: Masanobu
authors.initials: M
authors.lastname: Noda
authors.forename: Kazushi
authors.initials: K
authors.lastname: Takeda
authors.forename: Satoru
authors.initials: S
authors.lastname: Ueno
authors.forename: Toshio
authors.initials: T
authors.lastname: Inaba
authors.forename: Kayoko
authors.initials: K
authors.lastname: Kida
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Tamada
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sawada
mesh_terms: D000282:Administration, Intravaginal; D000818:Animals; D002417:Cattle / Q000502:physiology*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000378:metabolism; D004973:Estrus Synchronization; D005260:Female; D008183:Luteal Phase; D010060:Ovulation; D010121:Oxytocin / Q000378:metabolism / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D011863:Radioimmunoassay; D013997:Time Factors; D014599:Uterus / Q000378:metabolism*
chemical_list: C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost